Columbus Circle Investors’s Supernus Pharmaceuticals SUPN Stock Holding History

Columbus Circle Investors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-12,035	Closed	-$481K	–	263
2017 Q3	$481K	Buy	+12,035	New	+$521K	0.01%	277
2017 Q2	–	Sell	-58,035	Closed	-$1.82M	–	289
2017 Q1	$1.82M	Buy	58,035 +2,062	+4%	+$55.3K	0.03%	226
2016 Q4	$1.41M	Buy	+55,973	New	+$1.25M	0.02%	222

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Columbus Circle Investors's SUPN Position: Q4 2017 in Review

Columbus Circle Investors sold out of Supernus Pharmaceuticals (SUPN) in Q4 2017, closing a stake of 12,035 shares — an estimated $481K sold.

Columbus Circle Investors first reported a position in SUPN in Q4 2016 and held it in 3 quarters. The position peaked at $1.82M in Q1 2017. 297 funds tracked by Wall St. Rank hold SUPN as of Q4 2017.

Columbus Circle Investors reported no remaining Supernus Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Columbus Circle Investors sold 12,035 Supernus Pharmaceuticals shares in Q4 2017, an estimated $481K.
Columbus Circle Investors first reported a position in Supernus Pharmaceuticals in Q4 2016 and held it in 3 quarters.
Columbus Circle Investors's Supernus Pharmaceuticals position peaked at $1.82M in Q1 2017.
297 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2017.

Based on Columbus Circle Investors's 13F filing for Q4 2017, filed 2 Feb 2018.